PUR1800 (RV1162), A novel narrow spectrum kinase inhibitor, but not Fluticasone, reduces TNFa-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients

Curran, Aidan K.; Charron, Catherine E.; Russell, Paul; Hava, David L.

doi:10.1183/13993003.congress-2018.pa5247

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to fluticasone propionate, it reduced TNF-α-induced cytokine release from primary bronchial epithelial cells of healthy volunteers and COPD patients. 63 The preliminary pharmacokinetic data indicate that PUR1800 results in low and consistent systemic exposure in COPD patients when administered via oral inhalation. 64 …”

Section: Inhibition Of Recruitment and Activation Of The Inflammatory...mentioning

confidence: 96%

Novel Anti-Inflammatory Approaches to COPD

Cazzola¹,

Hanania²,

Page³

et al. 2023

COPD

View full text Add to dashboard Cite

Airway inflammation, driven by different types of inflammatory cells and mediators, plays a fundamental role in COPD and its progression. Neutrophils, eosinophils, macrophages, and CD4 + and CD8 + T lymphocytes are key players in this process, although the extent of their participation varies according to the patient's endotype. Anti-inflammatory medications may modify the natural history and progression of COPD. However, since airway inflammation in COPD is relatively resistant to corticosteroid therapy, innovative pharmacological anti-inflammatory approaches are required. The heterogeneity of inflammatory cells and mediators in annethe different COPD endo-phenotypes requires the development of specific pharmacologic agents. Indeed, over the past two decades, several mechanisms that influence the influx and/or activity of inflammatory cells in the airways and lung parenchyma have been identified. Several of these molecules have been tested in vitro models and in vivo in laboratory animals, but only a few have been studied in humans. Although early studies have not been encouraging, useful information emerged suggesting that some of these agents may need to be further tested in specific subgroups of patients, hopefully leading to a more personalized approach to treating COPD.

show abstract

Section: Inhibition Of Recruitment and Activation Of The Inflammatory...mentioning

confidence: 96%